HER-2 (HB5) Aptamer Details

ID# 7745

Back to Search Results

Structure

Chemistry

DNA

Target

HER2 peptide

Sequence (3-char table code)

G A C U/T

5'- dApdApdCpdCpdGpdCpdCpdCpdApdAp dApdTpdCpdCpdCpdTpdApdApdGpdAp dGpdTpdCpdTpdGpdCpdApdCpdTpdTp dGpdTpdCpdApdTpdTpdTpdTpdGpdTp dApdTpdApdTpdGpdTpdApdTpdTpdTp dGpdGpdTpdTpdTpdTpdTpdGpdGpdCp dTpdCpdTpdCpdApdCpdApdGpdApdCp dApdCpdApdCpdTpdApdCpdApdCpdAp dCpdGpdCpdApdCpdAp-3'

Molecular Weight: 26271.12

Extinction Coefficient: 811300

Binding Conditions / Buffer

Hanks buffer with 0.1 mg/mL salmon sperm DNA and 1 mg/mL of BSA

Binding Temp: 37°C

Refolding Protocol

If the oligo is a known aptamer sequence: For binding studies, perform a refolding protocol to ensure proper function (i.e. binding to antigen or target). Refer to the aptamer reference source for the appropriate refolding parameters and binding conditions. Note: it is unknown whether aptamer functions properly without refolding.

Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.

Reference

Z Liu et al. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10(2012): 148-157.

Request a Quote Have your aptamer oligo synthesized by Aptagen.